Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System.
暂无分享,去创建一个
J. Kwon | J. Hutcheon | A. Albert | S. Gill
[1] R. Cobin,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[2] C. Tseng. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. , 2015, Gynecologic oncology.
[3] J. Ioannidis,et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies , 2015, BMJ : British Medical Journal.
[4] L. Kuller,et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer , 2014, British Journal of Cancer.
[5] T. Stürmer,et al. Metformin and the risk of endometrial cancer: a population-based cohort study. , 2014, Gynecologic oncology.
[6] Travis L. Rodkey,et al. Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy , 2013, Molecular Cancer Therapeutics.
[7] W. Qi,et al. Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth , 2013, PloS one.
[8] R. Broaddus,et al. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. , 2013, American journal of obstetrics and gynecology.
[9] S. Jick,et al. Metformin and the risk of endometrial cancer: a case-control analysis. , 2013, Gynecologic oncology.
[10] T. Rohan,et al. A Prospective Study of Inflammation Markers and Endometrial Cancer Risk in Postmenopausal Hormone Nonusers , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[11] E. Gale,et al. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.
[12] Samy I McFarlane. Antidiabetic medications and weight gain: Implications for the practicing physician , 2009, Current diabetes reports.
[13] A. Donker,et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. , 2009, Archives of internal medicine.
[14] A. Thor,et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro , 2009, Cell cycle.
[15] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[16] Samy Suissa,et al. Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.
[17] Samy Suissa,et al. Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.
[18] C. Mantzoros,et al. Diabetes and Risk of Endometrial Cancer: A Population-Based Prospective Cohort Study , 2007, Cancer Epidemiology Biomarkers & Prevention.
[19] S. Majumdar,et al. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.
[20] R. DePinho,et al. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.
[21] R. Kaaks,et al. Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .
[22] T. Sellers,et al. Diabetes and endometrial cancer in the Iowa women's health study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[23] R. Misbin. Phenformin-associated lactic acidosis: pathogenesis and treatment. , 1977, Annals of internal medicine.